# US 2025/0145950 A1 · Methods for Activation and Expansion of T Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145950 A1
- Document ID: US20250145950A1
- Status: Published application
- Kind: A1
- Application number: 18/834,112
- Filed: 2023-02-01
- Published: 2025-05-08
- Earliest claimed: 2022-02-01
- Assignees: Alaunos Therapeutics, Inc.
- Applicants: Alaunos Therapeutics, Inc.
- Inventors: Drew Caldwell DENIGER; Lenka Victoria HURTON; Donghyun JOO; Yaoyao SHI; An LU; Victor CARPIO; Matthew COLLINSON-PAUTZ
- Web page: https://patentgrep.com/patent/US20250145950A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- C12N 15/85: for animal cells
- C12N 2500/32: Amino acids
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2501/2312: Interleukin-12 (IL-12)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2510/00: Genetically modified cells
- C12N 2800/90: Vectors containing a transposable element
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods for culturing and expanding lymphocytes using unconventional cytokines are provided. These methods include techniques for culturing and expanding lymphocytes using streamlined approaches, including approaches using agonists for stimulation, and approaches more suitable for clinical manufacturing. Compositions of expanded populations of lymphocytes are also provided.

## Claims

### Claim 1

A method of expanding a population of electroporated T cells comprising culturing the electroporated T cells with a first culture medium comprising one or more cytokines.

### Claim 2 (depends on 1)

The method of claim 1, wherein the electroporated T cells are contacted with the first culture medium within 12 hours of electroporation.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the one or more cytokines are selected from the group consisting of IL-7, IL-15, and IL-21.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the first culture medium further comprises an exogenous glutathione precursor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the glutathione precursor is N-acetylcysteine (NAC).

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein the first culture medium comprises IL-15.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein the first culture medium comprises IL-7.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the first culture medium comprises IL-21.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, wherein the first culture medium comprises IL-7 and IL-21.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9, wherein the electroporated T cells are electroporated prior to culturing with the first culture medium.

### Claim 11 (depends on 10)

The method of claim 10, wherein the electroporated T cells are cultured in the first culture medium for 6-12 hours after electroporation.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11 further comprising culturing the T cells with a second culture medium, wherein the second culture medium comprises one or more cytokines selected from the group consisting of IL-7, IL-12, and IL-21.

### Claim 13 (depends on 12)

The method of claim 12, wherein the second culture medium comprises IL-7, IL-12, and IL-21.

### Claim 14 (depends on 12, 13)

The method of claim 12 or 13, wherein IL-21 is added to the second culture medium every 2 to 3 days.

### Claim 15 (depends on 12, 13, 14)

The method of any one of claims 12 to 14, wherein at least one of the cytokines selected from the group consisting of IL-7 and IL-12 are added to the second culture medium only on the first day of culturing.

### Claim 16 (depends on 15)

The method of claim 15, wherein IL-7 and IL-12 are added to the second culture medium only on the first day of culturing.

### Claim 17 (depends on 12, 13, 14, 15, 16)

The method of any one of claims 12 to 16, wherein the T cells are cultured in the second culture medium after being cultured in the first culture medium.

### Claim 18 (depends on 12, 13, 14, 15, 16, 17)

The method of any one of claims 12 to 17, wherein the T cells are cultured in the second culture medium for 11 to 13 days.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1 to 18, further comprising culturing the T cells with a third culture medium, wherein the third culture medium comprises one or more cytokines selected from the group consisting of IL-2 and IL-21.

### Claim 20 (depends on 19)

The method of claim 19, wherein the third culture medium comprises IL-2.

### Claim 21 (depends on 19, 20)

The method of claim 19 or 20, wherein the third culture medium comprises IL-21.

### Claim 22 (depends on 19, 20, 21)

The method of any one of claims 19 to 21, wherein the third culture medium further comprises IL-12.

### Claim 23 (depends on 19, 20, 21, 22)

The method of any one of claims 19 to 22, wherein the third culture medium further comprises an exogenous glutathione precursor.

### Claim 24 (depends on 23)

The method of claim 23, wherein the exogenous glutathione precursor is NAC.

### Claim 25 (depends on 19, 20, 21, 22, 23, 24)

The method of any one of claims 19 to 24, wherein the third culture medium comprises IL-12, IL-21 and NAC.

### Claim 26 (depends on 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 19 to 25, wherein the third culture medium comprises IL-2, IL-12, IL-21 and NAC.

### Claim 27 (depends on 21, 22, 23, 24, 25, 26)

The method of any one of claims 21 to 26, wherein IL-21 is added to the third culture medium every 2 to 3 days.

### Claim 28 (depends on 20, 22, 23, 24, 25, 26)

The method of any one of claims 20 or 22 to 26, wherein IL-2 is added to the third culture medium every 3 to 4 days.

### Claim 29 (depends on 20, 22, 23, 24, 25, 26, 27)

The method of any one of claims 20 or 22 to 27, wherein IL-2 is present in the third culture medium in an amount from 30 U/ml to 3000 U/ml.

### Claim 30 (depends on 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 22 to 29, wherein the IL-12 is added to the third culture medium only on the first day of culturing.

### Claim 31 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 19 to 30, wherein the T cells are cultured in the third culture medium after being cultured in the second culture medium.

### Claim 32 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 19 to 31, wherein the T cells are cultured in the third culture medium for 11 to 13 days.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1 to 32, wherein the first, second and/or third culture media further comprise a TCR agonist.

### Claim 34 (depends on 33)

The method of claim 33, wherein the TCR agonist is a CD3 agonist.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1 to 34, wherein the first, second and/or third culture media further comprise an agonist of a T cell costimulatory molecule.

### Claim 36 (depends on 35)

The method of claim 35, wherein the agonist of a T cell costimulatory molecule is a CD28 agonist.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1 to 36, wherein the first, second and/or third culture media further comprise a nanomatrix.

### Claim 38 (depends on 37)

The method of claim 37, wherein the TCR agonist and/or the T cell costimulatory molecule is associated with the nanomatrix.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1 to 38, further comprising culturing the cells with feeder cells.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A population of engineered T cells manufactured according to the method of any one of claims 1 to 39.

### Claim 41 (depends on 40)

The population of engineered T cells of claim 40, wherein more than 10% of the engineered T cells in the population comprise one or more of the following: an exogenous TCR or functional fragment thereof, and an exogenous membrane-bound IL-15.

### Claim 42 (depends on 40)

The population of engineered T cells of claim 40, wherein more than 2% of the engineered T cells in the population co-express an exogenous TCR or functional fragment thereof and an exogenous membrane-bound IL-15.

### Claim 43

A population of engineered T cells, wherein more than 10% of the engineered T cells in the population comprise an exogenous TCR or functional fragment thereof, and wherein more than 20% of the population of engineered T cells are CCR7+/CD45RO+.

### Claim 44

A population of engineered T cells, wherein more than 10% of the engineered T cells in the population comprise an exogenous TCR or functional fragment thereof, and wherein more than 40% of the population of engineered T cells are CD95+/CD62L+.

### Claim 45 (depends on 44)

The population of engineered T cells of claim 44, wherein the population of engineered T cells comprise more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% CD45RA+CD45RO-CD62L+CD95+ cells.

### Claim 46 (depends on 44)

The population of engineered T cells of claim 44, wherein the population of engineered T cells comprise more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% CD45RA+CD45RO+CD62L+CD95+ cells.

### Claim 47

A population of cells comprising a polycistronic expression cassette comprising:
a. a first cistron comprising a polynucleotide sequence that encodes a fusion protein that comprises IL-15, or a functional fragment or functional variant thereof, and IL-15Rα, or a functional fragment or functional variant thereof;
b. a second cistron comprising a polynucleotide sequence that encodes a TCR beta chain comprising a Vβ region and a Cβ region; and
c. a third cistron comprising a polynucleotide sequence that encodes a TCR alpha chain comprising a Vα region and a Cα region.

### Claim 48 (depends on 47)

The population of cells of claim 47, wherein the population of cells are T cells that comprise more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% CD45RA+CD45RO-CD62L+CD95+ cells.

### Claim 49 (depends on 47)

The population of cells of claim 47, wherein the population of cells are T cells that comprise more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% CD45RA+CD45RO+CD62L+CD95+ cells.
